biotech / news / / Benzinga
Omvoh (mirikizumab-mrkz) was approved by the FDA in January 2025.
Over 63.5% of Omvoh-treated UC patients maintained disease clearance after four years in LUCENT-3.
KEY POINTS
- Omvoh is the first interleukin-23p19 inhibitor to show sustained disease clearance in UC for four years.
- 61.3% of patients maintained endoscopic normalization plus remission for four years with Omvoh.
- FDA approved Omvoh for moderately to severely active Crohn's disease in January 2025.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →